Does chronic hemolysis increase bilirubin production and complicate iron handling?

Chronic hemolysis significantly alters systemic iron and bilirubin metabolism by accelerating the destruction of red blood cells and overwhelming normal processing pathways. The claim that this process increases bilirubin production and complicates iron handling is well-supported by clinical and mechanistic evidence.

Clinical and mechanistic evidence

Chronic hemolysis serves as the primary driver for increased bilirubin and iron flux through several interconnected pathways:

• Bilirubin production: Approximately 80% of daily bilirubin comes from red blood cell turnover. In hemolytic states, the shortened lifespan of red cells releases an excess of heme substrate. This induces the rate-limiting enzyme heme oxygenase-1 (HO-1), which degrades heme into biliverdin and subsequently into unconjugated bilirubin. Because this process occurs in a fixed 1:1 ratio, bilirubin levels directly reflect the magnitude of hemolysis.
• Macrophage iron recycling: Hemolysis increases the delivery of hemoglobin and heme to splenic red pulp macrophages and hepatic Kupffer cells. This influx increases the intracellular labile iron pool, prompting the induction of HO-1 and the iron exporter ferroportin. In chronic states, this creates a high-volume throughput of iron from degraded red cells back into the systemic circulation.
• Ferritin and iron stores: The continuous processing of heme iron increases iron stores within macrophages, which is reflected by elevated serum ferritin levels. In non-transfused patients with chronic hemolysis, such as those with sickle cell disease or thalassemia, ferritin levels rise as a result of both increased recycling and increased intestinal absorption.

Complications in iron handling

Over time, the increased flux of iron through macrophages can lead to significant systemic complications:

• Hepcidin suppression: Chronic hemolysis often triggers "ineffective erythropoiesis," where the body attempts to compensate for red cell loss. This process releases erythroferrone, a hormone that suppresses hepatic hepcidin.
• Unregulated iron export: Low hepcidin levels remove the "brake" on ferroportin, the only known cellular iron exporter. This allows macrophages to dump iron into the plasma at an unrestricted rate.
• NTBI and oxidative damage: When the rate of iron export exceeds the binding capacity of transferrin (typically >70–80% saturation), non-transferrin-bound iron (NTBI) is formed. NTBI is highly reactive and is taken up unregulated by parenchymal cells in the heart, liver, and endocrine organs, leading to oxidative stress, organ fibrosis, and heart failure.

Bottom line

Chronic hemolysis increases bilirubin production and macrophage iron recycling through the induction of heme oxygenase-1. This process raises serum ferritin and, when combined with suppressed hepcidin, leads to unrestricted iron export and the formation of toxic non-transferrin-bound iron, which can cause progressive organ damage over time.